相关实验视频
Updated: Jan 10, 2026
09:07
Murine Model of Epicutaneously-Induced Immunomodulation
Published on: June 24, 2025
469
在N-ERD患者中,在乙烯基酸挑战期间,杜比卢马布会减缓粘膜2型反应
Julia Eckl-Dorna1, Christina Morgenstern1, Katharina Poglitsch2
1Department of Otorhinolaryngology, General Hospital and Medical University of Vienna, Vienna, Austria.
概括
在非类固醇抗炎药物加剧性呼吸道疾病 (N-ERD) 患者中,杜皮卢马布治疗在乙盐酸 (ASA) 挑战期间降低了鼻腔2型细胞因子. 这些变化独立于ASA耐受性发展而发生.
科学领域:
- 免疫学 免疫学 免疫学
- 呼吸系统医学 呼吸系统医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 非类固醇抗炎药物加剧的呼吸道疾病 (N-ERD) 涉及NSAID过敏,鼻多重症和喘.
- 导致N-ERD对乙酸 (ASA) 过敏的特定介质尚未完全理解.
研究的目的:
- 为了研究在N-ERD患者中ASA挑期间的鼻间介动力学.
- 评估dupilumab治疗对这些介导体和转录组特征的影响.
主要方法:
- 从N-ERD患者,CRSwNP患者和健康对照组中收集了鼻腔粘膜层液体.
- 在N-ERD患者中,在dupilumab治疗24周之前和之后进行了介质分析和转录组分析.
- ASA挑是在选定的时间点进行的.
主要成果:
- 在N-ERD患者中,ASA诱导显著增加了2型细胞因子 (TSLP,IL-5,eotaxin-3),而dupilumab则减少了这种效应.
- 杜皮卢马布治疗减少了2型途径基因的上调调节,并改变了脂质和过氧体代谢基因表达.
- 2型媒介体的变化与ASA耐受性的发展没有关联.
结论:
- 在ASA诱发期间,杜皮卢马布治疗减少了N-ERD患者的鼻腔2型细胞因子分泌.
- 转录组特征显示dupilumab后明显的变化,独立于耐受性发展.
- 需要进一步的研究来了解这些发现的临床影响.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
431
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
431
01:29Inflammatory Bowel Disease IV: Pharmacological Management
450
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
450
01:17Drugs for Treatment of Diarrhea-Predominant IBS
599
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
599
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
461
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
461
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
457
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
457
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
413
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
413